SVA Life Sciences proudly announces the appointment of Laura Jacanin as the new Life Sciences and Cell and Gene Therapy Director of Business Development. With over two decades of experience in driving transformative growth within the biopharmaceutical industry, Laura brings a wealth of expertise in accelerating clinical development portfolios, particularly in the dynamic fields of cell and gene therapy.
In her role, Laura will spearhead business development efforts aimed at empowering clients to optimize development timelines, reduce costs, and enhance the value of product assets through SVA's innovative solutions. Leveraging her extensive background in fostering successful partnerships and collaborating with executive teams, Laura is poised to drive strategic initiatives that propel SVA Life Sciences and its clients toward unprecedented success.
Prior to joining SVA Life Sciences, Laura held key leadership positions at renowned organizations including Lonza, Wuxi Advanced Therapies, Cytovance, and Genezen. Her tenure in these roles solidified her reputation as a dynamic business executive known for her ability to lead by example and deliver results.
Laura's unique skill set encompasses global strategic alliances, collaborative relationship-building, problem-solving, program management, practical conflict negotiation, and alternative dispute resolution. Her profound understanding of the complexities inherent in the cell and gene therapy landscape, coupled with her academic background, including a Master's degree in Dispute Resolution from Pepperdine Caruso School of Law, uniquely positions her to navigate challenges and drive innovation in today's evolving industry.
"We are thrilled to welcome Laura to the SVA Life Sciences team," said Bryan Bechtoldt, President of SVA Consulting. "Her wealth of experience, coupled with her dedication to fostering collaborative partnerships and driving meaningful change, will be instrumental in advancing our mission to revolutionize the future of healthcare."
With Laura's appointment, SVA Life Sciences reaffirms its commitment to excellence and innovation in the life sciences industry, positioning itself as a trusted partner in driving forward-thinking solutions that transform patient outcomes worldwide.
